NCT05069311|Completed
Loading search results
Sponsor study identifier
interventional
62
1 country
1
Study Start
October 15, 2021
Actual (reported)Primary Completion
March 30, 2022
Actual (reported)Study Completion
June 30, 2022
Actual (reported)The inflammatory process is the main mechanism in the occurrence of acute postoperative pain. It is also the main risk for the development of acute pain into persistent pain. Inflammation occurs in the process of peripheral sensitization and central sensitization with various inflammatory mediators. Postoperatively, there will be proliferation and activation of microglia and astrocytes which will then activate inflammatory receptors and signaling cascades of neurotransmitters, cytokines, and chemokines. There has been a lot of clinical research evidence that multimodal analgesia can adequately treat acute pain and can prevent the development of acute postoperative pain into persistent pain and chronic postoperative pain, but the molecular mechanisms are not fully understood.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 30, 2022
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 23, 2021
Actual (reported)October 6, 2021
Actual (reported)October 15, 2021
Actual (reported)March 30, 2022
Actual (reported)June 30, 2022
Actual (reported)Preoperative MCP-1
serum level of MCP-1
1-hour before surgery
Preoperative BDNF
serum level of BDNF
1-hour before surgery
Preoperative MiRNA-124
serum level of MiRNA-124
1-hour before surgery
Postoperative MCP-1
serum level of MCP-1
48-hours after surgery
Postoperative BDNF
Patients who undergo surgical hysterectomy that fits inclusion and exclusion criteria
Multimodal analgesia includes the combination of: 1. morphine given by PCA (patient-controlled analgesia) at 1 mg/dose 2. bupivacaine 0.25% and dexmedetomidine 0.5 mcg/mL (total volume of 10 mL) by epidural-catheter bolus given preoperatively 3. bupicavaine 0.125% and dexmedetomidine 0.5 mcg/mL at a 5 mL/hour rate per epidural-catheter given intraoperatively 4. bupivacaine 0.1% and dexmedetomidine 0.5 mcg/mL given by programmed intermittent epidural bolus (PIEB), set to be delivered every one-hour 5. etericoxib 90 mg per oral give two-hours before surgery and then continued until three days post-surgery 6. paracetamol 1 g (intravenously) given on the day of the surgery, continued at 10 mg/kg dose every 8 hours until three days post-surgery
Sanglah General Hospital
Denpasar, Bali, 80114, Indonesia
62 participants (actual enrollment reported by the registry).
First Submitted
September 23, 2021
First Posted
October 6, 2021
Study Start
October 15, 2021
Actual (reported)IVs With Buzzy in Chronic Pain Patients
serum level of BDNF
48-hours after surgery
Postoperative MiRNA-124
serum level of MiRNA-124
48-hours after surgery
Standard analgesia includes fentanyl 2 mcg/kg (bolus) and morphine given by PCA (patient-controlled analgesia) at 1 mg/dose
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
March 30, 2022
Actual (reported)Study Completion
June 30, 2022
Actual (reported)Last Updated
August 10, 2022
Record last verified: 2022-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: